Johnson & Johnson (JNJ) Non-Current Deffered Revenue (2009)
Johnson & Johnson (JNJ) posted Non-Current Deffered Revenue of $7.1 billion for Q3 2009, down 3.51% sequentially from $7.4 billion in Q2 2009.
Johnson & Johnson (JNJ) Non-Current Deffered Revenue (2009) Analysis & Trends
Johnson & Johnson (JNJ) has 1 years of Non-Current Deffered Revenue data on file, last reported at $7.1 billion in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 27, 2009 | 7.11 Bn |
| Jun 28, 2009 | 7.37 Bn |